Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer-Reference-Cited by-同舟云学术

Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer

Published:2021-12 Issue:12 Volume:23 Page:1886-1896
ISSN:1365-182X
Container-title:HPB
language:en
Short-container-title:HPB

Author:

Strijker Marin^ORCID,van der Sijde Fleur,Suker Mustafa,Boermeester Marja A.,Bonsing Bert A.^ORCID,Bruno Marco J.,Busch Olivier R.,Doukas Michail,van Eijck Casper H.,Gerritsen Arja,Groot Koerkamp Bas^ORCID,Haj Mohammad Nadia^ORCID,van Hilst Jony,de Hingh Ignace H.,van Hooft Jeanin E.^ORCID,Luyer Misha D.^ORCID,Quintus Molenaar I.,Verheij Joanne,Waasdorp Cynthia,Wilmink Johanna W.,Besselink Marc G.^ORCID,van Laarhoven Hanneke W.^ORCID,Bijlsma Maarten F.

Funder

KWF Kankerbestrijding

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference24 articles.

1. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal;Bijlsma;Canc Metastasis Rev,2015

2. Normalization of the vasculature for treatment of cancer and other diseases;Goel;Physiol Rev,2011

3. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy;Veenstra;Oncogenesis,2018

4. Phase I dose escalation study with expansion cohort of the addition of nab-paclitaxel to capecitabine and oxaliplatin (CapOx) as first-line treatment of metastatic esophagogastric adenocarcinoma (ACTION study);Schokker;Cancers,2019

5. The Dutch pancreas biobank within the Parelsnoer Institute: a nationwide biobank of pancreatic and periampullary diseases;Strijker;Pancreas,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant therapy for resectable pancreatic cancer: a narrative review;Journal of Pancreatology;2022-06

2. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB);JAMA Oncology;2022-06-01

3. Upregulation of ADAM12 Is Associated With a Poor Survival and Immune Cell Infiltration in Colon Adenocarcinoma;Frontiers in Oncology;2021-09-16